Yaoxue Xuebao

Submission On

( Vol 60 , Issue 04 ) |

15 Sep 2025
Day
Hour
Min
Sec
Publish On

( Vol 60 , Issue 03 ) |

31 Aug 2025
Scopus Indexed (2025) scopus
ABCD Indexed (2025) scopus
scopus

Yaoxue Xuebao

Yaoxue Xuebao (ISSN:0513-4870) is a monthly peer-reviewed scopus-indexed journal from 1960, from 1962 to 1966, from 1979 to Present. The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements. The journal welcomes all kind of research/review/abstract papers regarding Pharmacology, Toxicology and Pharmaceutics, General Pharmacology and Toxicology and Pharmaceutics Biochemistry, Genetics and Molecular Biology and Molecular Medicine and so on.

Aim And Scope

Yaoxue Xuebao

Pharmacology

Toxicology and Pharmaceutics

General Pharmacology

Toxicology and Pharmaceutics Biochemistry

Genetics and Molecular Biology

Molecular Medicine

Latest Journal

Yaoxue Xuebao

  • YX-18-11-2024-2121
  • | Yaoxue Xuebao (ISSN:0513-4870)

Pharmacokinetic effects of metformin hydrochloride, food and alcohol on Ramulus Mori (Sangzhi) alkaloids

Ramulus Mori (Sangzhi) alkaloids (SZ-A) are a group of polyhydroxy alkaloids extracted and isolated from the traditional Chinese medicine mulberry twig, which is mainly used for the treatment of type 2 diabetes mellitus (T2DM). In addition to acting as a glycosidase inhibitor in the small intestine after oral administration, SZ-A can also be absorbed into blood and widely distributed to target organs related to diabetes, exerting multiple pharmacological effects. It is important to elucidate the possible pharmacokinetic influences of SZ-A for its clinical rational applications, such as drug

read more..
  • YX-18-11-2024-2120
  • | Yaoxue Xuebao (ISSN:0513-4870)

Hepatoprotective activity of Zha Xun and its different solvent-eluting components

A pharmacophore-based study was conducted to investigate the therapeutic activity of the traditional Tibetan medicine Zha Xun (ZX) in liver diseases. In the present study, the protective effect of ZX on the acute liver injury induced by concanavalin A (ConA) and 0.15% carbon tetrachloride (0.15% CCl4) in ICR mice was evaluated, and the results showed that ZX significantly reduced serum alanine aminotransferase ( ALT) and aspartate aminotransferase (AST) in the ConA-induced acute immune liver injury model and the CCl4-induced acute oxidative liver injury model (P < 0.05). Subsequently, th

read more..
  • YX-18-11-2024-2119
  • | Yaoxue Xuebao (ISSN:0513-4870)

Neuroprotective and mechanistic study of GJ-4 on okadaic acid-induced memory impairment in mice

GJ-4 is crocin enrichments extracted from Gardenia jasminoides J. Ellis, and our previous studies have shown that GJ-4 significantly improved learning and memory impairment induced by Aβ in mice. Herein, a memory deficit model was developed by injecting okadaic acid (OA) into the lateral ventricle of mice, and the neuroprotection and underlying mechanism of GJ-4 on neuronal injury caused by Tau hyperphosphorylation were investigated. The Animal Care & Welfare Committee, Institute of Materia Medica, CAMS & PUMC has approved all procedures (No.00000318). GJ-4 at different doses w

read more..
  • YX-18-11-2024-2118
  • | Yaoxue Xuebao (ISSN:0513-4870)

Global progress in peptide radiopharmaceutical research and China's opportunities

Radiopharmaceutical is an essential component of nuclear medicine and molecular imaging, as well as a key component of precision medicine. The United States Food and Drug Administration (FDA) has recently approved the marketing of several peptide-based radiopharmaceuticals, sparking a global trend of research in this area and propelling nuclear medicine into the precision theranostic era. This has created a new wave of technological competition in the field of nuclear medicine. It is the responsibility of Chinese scientists in the radiopharmaceutical field to capitalize on this opportunity,

read more..
  • YX-18-11-2024-2117
  • | Yaoxue Xuebao (ISSN:0513-4870)

Research progress on cardiovascular toxicity associated with anti-tumor drugs and its prevention and treatment

Cancer and cardiovascular diseases are the two major causes of death worldwide. The application of anti-tumor drugs has significantly improved the prognosis of patients, the cardiovascular toxicity caused by the application of them has become an important factor affecting the survival and prognosis of cancer patients. Therefore, the prevention and treatment of cardiovascular toxicity related to cancer treatment is increasingly important. The cardiovascular toxicity associated with anti-tumor drugs exhibits different clinical manifestations and involves multiple pathological mechanisms. This

read more..

The publisher of this journal is Chinese Pharmaceutical Association. Yaoxue Xuebao committed to gathering and disseminating excellent research achievements.

Information
Guidelines
Contact Us
  • journalpublication435@gmail.com
  • admin@yaoxuexuebao-05134870.com
  • support@yaoxuexuebao-05134870.com
All rights reserved | © 2024 Yaoxue Xuebao (ISSN:0513-4870).